[Pharmacological and biochemical effects of hydralazine and dihydralazine].
D000311:Adrenal Glands / Q000032:analysis; D000818:Animals; D000959:Antihypertensive Agents / Q000378:metabolism / Q000494:pharmacology*; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001775:Blood Circulation / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D002247:Carbon Isotopes; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D002395:Catecholamines / Q000032:analysis; D002415:Cats; D002490:Central Nervous System / Q000187:drug effects; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D003864:Depression, Chemical; D004285:Dogs; D004983:Ethanolamines / Q000494:pharmacology; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D066298:In Vitro Techniques; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009206:Myocardium / Q000032:analysis; D011817:Rabbits; D051381:Rats; D013154:Spleen / Q000032:analysis; D013565:Sympatholytics / Q000494:pharmacology
D000959:Antihypertensive Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002247:Carbon Isotopes; D002395:Catecholamines; D002800:Cholinesterase Inhibitors; D004983:Ethanolamines; D008996:Monoamine Oxidase Inhibitors; D013565:Sympatholytics; D006830:Hydralazine; D002262:Carboxy-Lyases
Pharmakologische und biochemische Wirkungen von Hydralazin und Dihydralazin.